Commentary reflects on GAVI's approach to enhance vaccine policy for maximum impact on AMR.
In this commentary, we reflect on GAVI’s experience incorporating an antimicrobial resistance (AMR) criterion into the Vaccine Investment Strategy to explore how global vaccine policy can more integrate AMR objectives, and identify priority actions for maximizing the AMR impact of vaccines. This article is part of the Royal Society Science+ meeting issue ‘Vaccines and antimicrobial resistance: from science to policy’.
No takes yet. Share an insight, caveat, or question.
Jadeja et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: